Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Case Series of Non-Hodgkin's Lymphoma Recurrence in Lower Extremities Mimicking Deep Vein Thrombosis

Shelly Ann Christiansen, MD, Philip Cohen, MD, Catherine Broome, MD

Blood (2016) 128 (22): 5344.

https://doi.org/10.1182/blood.V128.22.5344.5344

Published: 2016

Journal Articles

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Guang Yang, Sara J. Buhrlage, Li Tan, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Jiaji G. Chen, Christopher J. Patterson, Jennifer R. Brown, Jorge J. Castillo, Wei Zhang, Xiaofeng Zhang, Shuai Liu, Philip Cohen, Zachary R. Hunter, Nathanael Gray, Steven P. Treon

Blood (2016) 127 (25): 3237–3252.

https://doi.org/10.1182/blood-2016-01-695098

Published: 2016

Journal Articles

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

Guang Yang, PhD, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Philip Cohen, Li Tan, PhD, Sara Buhrlage, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 4004.

https://doi.org/10.1182/blood.V126.23.4004.4004

Published: 2015

Journal Articles

An Association Between Hodgkin’s Lymphoma and Crohn’s Disease: A Case Series

Chaitra S. Ujjani, MD, Philip Cohen, MD

Blood (2014) 124 (21): 1611.

https://doi.org/10.1182/blood.V124.21.1611.1611

Published: 2014

Journal Articles

Lenalidomide Following Rituximab and Fludarabine in Untreated CLL

Chaitra S. Ujjani, MD, Edmund Gehan, PhD, Saad Jamshed, MD, Jeanette Crawford, Catherine Broome, MD, Philip Cohen, MD, Bruce D. Cheson, MD

Blood (2012) 120 (21): 3924.

https://doi.org/10.1182/blood.V120.21.3924.3924

Published: 2012

Journal Articles

Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.

Richard H. Van der Jagt, MD, Philip Cohen, MD, Bruce D. Cheson, MD, Anil Tulpule, MD, Jordan A. Herst, MD,FRCP, Bernard Lemieux, MD, Lee S. Schwartzberg, MD, Katherine Sue Robinson, MD, Jennifer W. Oliver, MD, Michael E. Williams, MD

Blood (2006) 108 (11): 2710.

https://doi.org/10.1182/blood.V108.11.2710.2710

Published: 2006

Journal Articles

Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta) , is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis

Jack L. Arbiser, Tweeny Kau, Martha Konar, Krishna Narra, Ramani Ramchandran, Scott A. Summers, Chris J. Vlahos, Keqiang Ye, Betsy N. Perry, William Matter, Anthony Fischl, James Cook, Pamela A. Silver, Jenny Bain, Philip Cohen, David Whitmire, Scott Furness, Baskaran Govindarajan, J. Phillip Bowen

Blood (2006) 109 (2): 560–565.

https://doi.org/10.1182/blood-2006-06-029934

Published: 2006

Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Katherine Sue Robinson, MD, Michael E. Williams, MD, Philip Cohen, MD, Anil Tulpule, MD, Richard H. van der Jagt, MD, Jordan A. Herst, MD, Robin M. Joyce, MD, Alberto Bessudo, MD, Bernard Lemieux, MD, Lee S. Schwartzberg, MD, Jennifer Oliver, MD, Ely Benaim, MD

Blood (2005) 106 (11): 923.

https://doi.org/10.1182/blood.V106.11.923.923

Published: 2005

Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

Jonathan W. Friedberg, MD, Philip Cohen, MD, Bruce D. Cheson, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Luis Fayad, MD, Ann S. La Casce, MD, Alberto Bessudo, MD, Elber S. Camacho, MD, Michael E. Williams, MD, Richard H. van der Jagt, MD, Jennifer Oliver, MD, Ely Benaim, MD

Blood (2005) 106 (11): 229.

https://doi.org/10.1182/blood.V106.11.229.229

Published: 2005

Journal Articles

ZAP-70 Expression in Chronic Lymphocytic Leukemia (CLL) Is Independent of Rai Stage: A Retrospective Review of 38 Patients (pts).

Blanche H. Mavromatis, MD, Bruce D. Cheson, MD, Nicole D. Zantek, MD, Dan-Paul Hartmann, PhD, Craig Kessler, MD, Philip Cohen, MD, Edmund Gehan, PhD, Metin Ozdemirli, MD

Blood (2004) 104 (11): 4811.

https://doi.org/10.1182/blood.V104.11.4811.4811

Published: 2004

Journal Articles

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Jonathan Friedberg, MD, Philip Cohen, MD, Robert O. Kerr, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Richard van der Jagt, MD, Elber Camacho, MD, John Hainsworth, MD, Brent Roeck, Pratik S. Multani, MD

Blood (2004) 104 (11): 2480.

https://doi.org/10.1182/blood.V104.11.2480.2480

Published: 2004

NARROW

A Case Series of Non-Hodgkin's Lymphoma Recurrence in Lower Extremities Mimicking Deep Vein Thrombosis

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

An Association Between Hodgkin’s Lymphoma and Crohn’s Disease: A Case Series

Lenalidomide Following Rituximab and Fludarabine in Untreated CLL

Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.

Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta) , is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Bendamustine HCl (TREANDA TM ) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

ZAP-70 Expression in Chronic Lymphocytic Leukemia (CLL) Is Independent of Rai Stage: A Retrospective Review of 38 Patients (pts).

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only